Summit Therapeutics
Open
$13.98
Prev. Close
$13.97
High
$14.06
Low
$13.92
Market Snapshot
$10.86B
-9.0
-0.00
265
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 265 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Summit Therapeutics shows improved performance metrics over Ainos, indicating a promising trajectory within the pharmaceutical industry and potential for significant future growth.
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 265 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Recently from Cashu
Summit Therapeutics Reports Promising Phase III Results for Lung Cancer Treatment Ivonescimab
Summit Therapeutics (Ticker: SMMT) has made significant strides in the fight against advanced squamous non-small cell lung cancer (NSCLC) with the recent announcement of positive results from its Phas…
Summit Therapeutics Reports Major Progress in Lung Cancer Treatment with Ivonescimab Trial Results
Summit Therapeutics has announced significant advancements in its drug development efforts through its collaboration with Akeso. The two companies report promising results from a late-stage trial of i…
Summit Therapeutics: Overview and Key Developments in Current Research and Business Strategy
I apologize for the confusion, but I currently don't have access to external links or the ability to retrieve articles. However, if you share the content you'd like summarized, I can create an article…
Need specific article text to summarize and reference Summit Therapeutics; clarify details.
I can help summarize content once you provide the specific article text or link you want me to work with. As for your questions: - Please confirm if you want the summary to be exactly 300 words or if…